To answer that question, I found what Stephen Barret M.D. had to say in a recent article in Dental Watch. In 2013, the Canadian Agency for Drugs and Technologies in Health searched the literature and located 13 studies of ViziLite and two other light-based screening adjuncts, VELscope and Identafi. The reviewers concluded that the available evidence does not support the use of the evaluated tools for the screening of cancer in the general population or those at low risk for malignancy. None of the studies measured cost-effectiveness [22]. ViziLite's promoters would like you to believe that the risk of getting oral cancer is high and that all adults should undergo annual screening with ViziLite Plus. The key question, however, is how often such screening will find precancerous changes in the mucous membranes not visible with the naked eye that, if found, would lead to increased survival. As far as I can tell, the answer is not often enough to make the test worthwhile, stated Dr. Barret.